What is the Advanta Immuno-Oncology Gene Expression Assay?
The Advanta™ Immunology-Oncology Gene Expression Assay qPCR assay panel enables profiling of tumor immunobiology and identification of new biomarkers. It was designed to meet the rigorous demands of human checkpoint research programs. It includes key markers of tumor immune response that were shown in a multicenter international clinical trial to inform tumor progression and checkpoint therapeutic response. See Herbst, R.S. et al., Nature 515 (2014): 563–67 and Fehrenbacher, L. et al., The Lancet 387 (2016): 1,837–46.
In collaboration with leading researchers and biopharmaceutical companies, Fluidigm further expanded this panel to include 74 additional immuno-oncology markers.